Principles and practice of HIV-protease inhibitor pharmacoenhancement

HIV Medicine

Volumn 2, Issue 2, 2001, Pages 105-113

  Moyle, G J ^a   Back, D ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; BINDING PROTEIN; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG RESISTANCE; DRUG TOXICITY; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NAUSEA; NEPHROLITHIASIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION;

ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; METABOLIC CLEARANCE RATE; MUTATION; VIRUS REPLICATION;

EID: 0035198762     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00063.x     Document Type: Review

References (38)

1. 1998 revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals
2. Antiretroviral therapy for HIV infection in 1998
3. Multiple dose pharmacokinetics of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects
4. Saquinavir systemic exposure and safety of once daily administration of Fortovase (saquinavir) soft gel capsule (FTV) in combination with low dose ritonavir
5. The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects
6. Multiple dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir combinations in healthy volunteers
7. Pharmacokinetic interactions between ritonavir and amprenavir in healthy volunteers
8. A randomized study comparing continued indinavir (800 mg tid) vs switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside and Safety Trial (BEST)
9. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800mg improves virologic response even after multiple failure
10. Nelfinavir: A review of its therapeutic efficacy in HIV infection
11. Relationships between exposure of saquinavir monotherapy and antiviral response in HIV-positive patients
12. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotype guided therapy: Pharmacological data from the Viradapt study
13. Efficacy of ABT-378/r vs nelfinavir (NFV) in antiretroviral (ARV)-naïve subjects: Results of a phase III blinded randomized clinical trial
14. Efficacy of a five drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
15. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 week safety/efficacy evaluation in multiple PI experienced patients
16. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
17. Lipid abnormalities during saquinavir-soft gel based HAART
18. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
19. Lipid profiles in patients on ritonavir / indinavir-containing therapy
20. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
21. Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection
22. Risk-benefit assessment of HIV protease inhibitors
23. Analysis of safety data from ABT-378/ritonavir (ABT-378/r) in two phase II clinical trials
24. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV seronegative subjects after multiple oral dosing
25. Efficacy of amprenavir (APV) 600 mg plus low-dose ritonavir (RTV) in clinical practice
26. Crystalluria and urinary tract abnormalities associated with indinavir
27. Changes in renal function associated with indinavir
28. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
29. Increased plasma drug levels using twice daily ritonavir-indinavir at 100-800mg correlate with virologic response in a salvage therapy
30. Does ritonavir 'baby dose' induce specific mutations in salvage combination therapy? A Viradapt sub-study
31. Antiretroviral drug level monitoring: The next routine test in HIV management?
32. Multiple dose pharmacokinetics and tolerability of indinavir (IDV) with ritonavir (RTV) and efavirenz (EFV) combinations in a once-daily regimen in healthy volunteers (Merck 093)
33. A pharmacokinetic (PK) stduy to investigate the influence of efavirenz (EFV) on a BID indinavir (IDV) /ritonavir (RTV) regimen (800/100 mg) in healthy volunteers
34. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
35. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
36. Pharmacokinetics of the triple combination of saquinavir, ritonavir and efavirenz in HIV-positive patients